To determine whether TP53 mutation has predictive value in HER2+ breast cancer patients, we first analyzed ctDNA sequencing results and the efficacy of pyrotinib in phase Ib, phase Ic, and phase II clinical trials led by our center. This evidence concerns the gene ERBB2 and breast cancer.